GlassScriptPhysician profile
Robert Whisnant
NPI 1609863513
$83,880.23
in general payments reported to CMS, 2019-2025
23 companies · $26.86 in 2025
The $26.86 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $24K · 2021: $24K · 2022: $5,878 · 2023: $167 · 2025: $26.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roanoke Area Surgical Lasers, LLC | $81,250.00 | 2019-2022 | |
| Astellas Pharma US INC | $1,082.87 | 2019-2022 | |
| Pfizer INC. | $353.69 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $241.15 | 2019-2023 | Xiaflex, Aveed |
| Myovant Sciences INC. | $156.54 | 2021-2022 | |
| Blue Earth Diagnostics | $137.05 | 2019-2022 | |
| Abbvie INC. | $93.27 | 2022-2025 | Botox, Lupron Depot |
| Urovant Sciences INC | $81.44 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $70.96 | 2023 | Orgovyx, Gemtesa |
| Karl Storz Endoscopy-America | $69.70 | 2019-2020 | |
| Olympus America INC. | $55.04 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.42 | 2019 | |
| Neotract INC. | $39.84 | 2020 | |
| Photocure INC | $32.67 | 2019-2021 | |
| 180 Medical, INC. | $26.82 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $26.30 | 2019-2020 | |
| Teleflex LLC | $20.09 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $18.96 | 2019 | |
| Allergan, INC. | $15.79 | 2019 | |
| Urogen Pharma, INC. | $15.43 | 2020 | |
| Travere Therapeutics, INC. | $13.92 | 2019-2022 | |
| Janssen Biotech, INC. | $13.78 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$188,710.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Whisnant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.